ABSTRACT
The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients had minor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.
Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.
Dr. Kelley received grant support from Bristol Myers Squibb during conducting of the study. This work was funded by a grant from Bristol Myers Squibb. The Department of Veterans Affairs provided indirect research support for the clinical trial at the Durham VA Medical Center.